Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07526571 · ClinicalTrials.gov registry record · NA

GLOW Study: Effects of Triple Protein in Women

A NA study, sponsored by University of North Carolina, Chapel Hill.

Recruiting
Registry status
NA
Development phase
40
Enrollment target

NCT07526571: Recruiting NA study, sponsored by University of North Carolina, Chapel Hill.

NCT07526571 is a NA study that is actively recruiting participants, run by University of North Carolina, Chapel Hill. The registered enrollment target is 40 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07526571, a NA study, is actively recruiting participants, sponsored by University of North Carolina, Chapel Hill.

RECRUITING
Registry status
NA
Development phase
40 participants
Enrollment target

Study Summary

This single-site, randomized, blinded, placebo-controlled study will evaluate whether 4 weeks of daily Triple Support Protein powder improves glycemic control and overall well-being in healthy women aged 30-60 years. Participants will undergo baseline testing (DXA, fasting blood, standardized meal test with 2-hour glucose and insulin sampling), complete one acute supervised dose, and then consume a daily supplement for 4 weeks. During the final 14 days, participants will wear a continuous glucose monitor. Outcomes include postprandial glucose AUC, insulin sensitivity, and body composition.

Primary Outcome

Glucose measured at 0-120 minutes post-meal; AUC by trapezoidal method.

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Triple protein support

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2026-04
Est. Completion 2026-12-01
Phase NA

What NCT07526571 shows while recruiting

NCT07526571 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT07526571 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT07526571 about?

NCT07526571 is a clinical study titled "GLOW Study: Effects of Triple Protein in Women". This single-site, randomized, blinded, placebo-controlled study will evaluate whether 4 weeks of daily Triple Support Protein powder improves glycemic control and overall well-being in healthy women aged 30-60 years. Participants will undergo baseline testing (DXA, fasting blood, standardized meal t...

What is the current status of trial NCT07526571?

This trial is currently recruiting. It is a NA study. The enrollment target is 40 participants. The study started on 2026-04. Estimated completion is 2026-12-01.

What interventions are being tested in trial NCT07526571?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Triple protein support (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07526571?

This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT07526571's enrollment target sits among peer trials

40 1447th of 2000 higher than 465 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT07526571, the US trial registry maintained by the National Library of Medicine. NCT07526571 (small enrollment · none site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.